Drug Trial Radar · NCT00680732
Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component
Last checked: Nov 19, 2026Latest source record: Sep 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,370
Actual
Start
Jun 2003
Primary completion
Oct 2006
Study completion Oct 2006
Sponsor
- Lead sponsor
- Institute of Tropical Medicine, BelgiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Departments of Parasitology and Public Health, ITM, Antwerp, Belgium; Centre Muraz; Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso
- First posted
- May 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 15 years, up to 44 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our objective was to investigate the importance of malaria infection/disease during pregnancy and more particularly during the first trimester; we also looked at the maternal-foetal interactions and their influence on the subsequent child's response to malaria infections during the first year of life. This study was carried out !in the same population recruited for the IUGR study (NCT00642408).
Conditions
- Malaria
- Malaria in Pregnancy
Interventions
Multiple micronutrients supplements (MMS)Dietary supplement
Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
Iron and folic acid (IFA)Dietary supplement
Iron 60 mg and folic acid 400 mcg
Chloroquine (CQ)Drug
Tablets 100 mg of chloroquine base
Sulphadoxyne-pyrimethamine (SP)Drug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of standard antimalarial treatment in preventing clinical malaria in pregnant women under weekly chemoprophylaxis or intermittent treatment.Time frame: Up to delivery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Muraz
Bobo-Dioulasso, Burkina Faso
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.